cas 405939-28-8, (4-IODO-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER

Articles about 405939-28-8Total 6 be found

(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
A series of β-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S
Edmondson, Scott D.,Mastracchio, Anthony,Mathvink, Robert J.,He, Jiafang,Harper, Bart,Park, You-Jung,Beconi, Maria,Di Salvo, Jerry,Eiermann, George J.,He, Huaibing,Leiting, Barbara,Leone, Joseph F.,Levorse, Dorothy A.,Lyons, Kathryn,Patel, Reshma A.,Patel, Sangita B.,Petrov, Aleksandr,Scapin, Giovanna,Shang, Jackie,Roy, Ranabir Sinha,Smith, Aaron,Wu, Joseph K.,Xu, Shiyao,Zhu, Bing,Thornberry, Nancy A.,Weber, Ann E.
p. 3614 - 3627
(2007/10/03)

Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors
Pathological angiogenesis is associated with disease states such as cancer, diabetic retinopathy, rheumatoid arthritis, endometriosis, and psoriasis. There is much evidence that direct inhibition of the kinase activity of vascular endothelial growth facto
Kuo, Gee-Hong,Wang, Aihua,Emanuel, Stuart,DeAngelis, Alan,Zhang, Rui,Connolly, Peter J.,Murray, William V.,Gruninger, Robert H.,Sechler, Jan,Fuentes-Pesquera, Angel,Johnson, Dana,Middleton, Steven A.,Jolliffe, Linda,Chen, Xin
p. 1886 - 1900
(2007/10/03)

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors
On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and
Kuo, Gee-Hong,DeAngelis, Alan,Emanuel, Stuart,Wang, Aihua,Zhang, Yan,Connolly, Peter J.,Chen, Xin,Gruninger, Robert H.,Rugg, Catherine,Fuentes-Pesquera, Angel,Middleton, Steven A.,Jolliffe, Linda,Murray, William V.
p. 4535 - 4546
(2007/10/03)

Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR
3,7-Diarylsubstituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility.
Wu, Zhicai,Fraley, Mark E.,Bilodeau, Mark T.,Kaufman, Mildred L.,Tasber, Edward S.,Balitza, Adrienne E.,Hartman, George D.,Coll, Kathleen E.,Rickert, Keith,Shipman, Jennifer,Shi, Bin,Sepp-Lorenzino, Laura,Thomas, Kenneth A.
p. 909 - 912
(2007/10/03)

SUBSTITUTED TRIAZINE KINASE INHIBITORS
The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.
-
Page 36-38

(2010/11/30)

PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
-
Page 84-85

(2010/02/07)